Pharma expects confirmation of acceptance from the FDA and a Prescription Medication User Fee Act goal date within the next few weeks. The Company anticipates a six-month review by FDA.P. Pharma and brings this important therapeutic option one step closer to cancer patients suffering from CINV, said John B. Whelan, A.P. Pharma’s president and chief executive officer. Now that we have resubmitted the NDA, our focus shall shift to pre-marketing and pre-commercialization actions in anticipation of potential FDA acceptance of APF530.Kaiser Family Foundation. Kaiser Health Information, an independent news service editorially, is a scheduled program of the Kaiser Family members Foundation, a nonpartisan health care policy research corporation unaffiliated with Kaiser Permanente. , a biotechnology business developing novel immune system activating treatments for cancers and infectious illnesses, announced that Phase 2 results of Prophage G-200 vaccine in recurrent sufferers with glioblastoma multiforme were hailed as 'interesting' and a 'extremely promising therapy' within an editorial released in Neuro-Oncology, the leading journal of the Culture of Neuro-Oncology. The results of Agenus' Prophage vaccine Phase 2 study, published last month in Neuro-Oncology, demonstrated that a lot more than 90 percent of the sufferers treated with the vaccine applicant were alive at six months.